Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Hemogenyx Pharmaceuticals PLC Announces CDX Development Update

By: ACCESSWIRE

September 01, 2024 at 22:00 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

CDX Development Update

LONDON, UNITED KINGDOM / ACCESSWIRE / September 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)("Hemogenyx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, is pleased to announce that it has developed a new and improved version of its bi-specific antibody ("CDX") for the treatment of relapsed/refractory acute myeloid leukaemia ("AML"), a subset of acute lymphoblastic leukaemia ("ALL"), and potentially for conditioning in bone marrow transplantations.

The Company's scientists utilised Lonza's bYlok bispecific pairing technology to develop a new and improved version of CDX, which has demonstrated significantly enhanced efficacy in in vitro testing. Additional in vivo studies are currently underway.

Dr. Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals, commented:

"The development of an improved version of our CDX bi-specific antibody holds significant promise for enhancing treatment outcomes for patients battling often incurable blood cancers. This advancement could accelerate the progress of this product candidate and allow us to resume its development toward the clinic. It may also attract new industry partners interested in fast-tracking the co-development of CDX."

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

About AML

AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.

About ALL

Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that primarily affects children, although it can also occur in adults. Unlike Acute Myeloid Leukemia (AML), ALL is characterized by the rapid proliferation of immature lymphocytes, a type of white blood cell. ALL is the most common childhood cancer, representing approximately 25% of cancer diagnoses in children. It progresses quickly and requires prompt treatment. While the overall prognosis for ALL is generally more favorable than AML, certain subtypes remain challenging to treat. Hemogenyx Pharmaceuticals is developing innovative treatments specifically targeting a subset of ALL that has proven particularly difficult to treat, especially in children. The Company's R&D focuses on addressing the limitations of current therapies and improving outcomes for patients with these hard-to-treat forms of ALL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on accesswire.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	226.65	-4.21 (-1.82%)
AAPL	338.19	-1.89 (-0.56%)
AMD	429.56	-25.06 (-5.51%)
BAC	61.07	-1.55 (-2.48%)
GOOG	335.76	+3.16 (0.95%)
META	585.61	-7.80 (-1.31%)
MSFT	390.54	-2.81 (-0.71%)
NVDA	190.01	-7.00 (-3.55%)
ORCL	117.74	-2.22 (-1.85%)
TSLA	298.32	-9.12 (-2.97%)